Skip to main content
padlock icon - secure page this page is secure

Identifying Biomarkers of Lung Cancer in the Post-Genomic Era

Buy Article:

$68.00 + tax (Refund Policy)

In the last two decades, we have witnessed an exponential growth of our knowledge on cell growth and neoplastic transformation at the molecular level. There is high expectation that these advances will be translated into further improvement in the care of cancer patients, especially in the areas of diagnosis, prognosis and treatment. With the completion of the human genome project and numerous studies on gene expression analyses in lung cancer, our challenge is to understand the tumor morphological changes at the molecular level, which will ultimately lead to novel approaches for patient care. This review will summarize methods for identifying biomarkers of lung cancer and molecular/genetic changes that have been investigated as candidate diagnostic, prognostic and predictive markers for lung cancer. A more concerted and global approach to study the clinical relevance of molecular changes in lung cancers is required in the future.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Myeloperoxidase; P53 Polymorphisms; Tissue microarray (TMA); cDNA array; comparative genomic hybridization; small cell lung cancer (SCLC)

Document Type: Review Article

Affiliations: Sealy Centers for Cancer Cell Biology and Environmental Health, Department of Pharmacology and Toxicology, University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX 77555-1048, USA.

Publication date: December 1, 2005

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more